Company profile: Repertoire
1.1 - Company Overview
Company description
- Provider of clinical-stage immune medicines, offering the DECODE platform to identify TCRs and disease-relevant epitopes across all human HLAs; off-the-shelf TCR bispecific therapeutics that engage T cells via tumor-specific epitopes and an anti-CD3 moiety; mRNA cancer vaccines delivered via lipid nanoparticles; and mRNA tolerizing vaccines to induce T-cell anergy and expand regulatory T cells for autoimmune diseases.
Products and services
- DECODE Platform: Pan-HLA suite that identifies TCRs and disease-relevant epitopes across all human HLAs, enabling development of immune medicines
- MRNA Cancer Vaccines: Lipid nanoparticle-delivered, off-the-shelf vaccines that activate cytotoxic T cells against tumors using epitopes encoded by mRNA
- TCR Bispecific Immune Medicines: Off-the-shelf therapeutics that target and eliminate tumors by engaging T cells through a tumor-specific epitope and an anti-CD3 moiety
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Repertoire
IMMCO Diagnostics
HQ: United States
Website
- Description: Provider of innovative medical devices, diagnostic laboratory testing expertise, and pioneering research for a comprehensive solution to autoimmune disease diagnostics.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full IMMCO Diagnostics company profile →
Kither Biotech
HQ: Italy
Website
- Description: Provider of pharmaceutical drug development targeting chronic inflammatory diseases, with inhaled therapies such as KIT2014, a cAMP-modulating peptide add-on for cystic fibrosis that enhances CFTR function, reduces mucus, and limits airway inflammation, and KITCL27, an inhaled PI3K-inhibitor prodrug for idiopathic pulmonary fibrosis activated in target cells to minimize systemic side effects.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Kither Biotech company profile →
Blade Therapeutics
HQ: United States
Website
- Description: Provider of discovery-stage drug development focused on oral, small-molecule therapies for fibrotic and neurodegenerative diseases, including cudetaxestat—a Phase 2-ready, non-competitive autotaxin inhibitor for idiopathic pulmonary fibrosis; BLD-2184—an IND-ready candidate for neurodegenerative diseases; a class of autotaxin inhibitors; and calpain inhibitors targeting dimeric calpains.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Blade Therapeutics company profile →
Immunic Therapeutics
HQ: United States
Website
- Description: Provider of selective oral immunology therapies, developing: Vidofludimus Calcium (IMU-838), an investigational oral drug for multiple sclerosis and other chronic inflammatory and autoimmune diseases with neuroprotective, anti-inflammatory and anti-viral effects; IMU-856, a Sirtuin 6–targeting small molecule to restore intestinal barrier and regenerate bowel epithelium for gastrointestinal diseases; and IMU-381, a next-generation GI candidate in preclinical testing.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Immunic Therapeutics company profile →
Kadmon
HQ: United States
Website
- Description: Provider of biopharmaceutical products and services for the treatment and management of hepatitis C, including Ribasphere RibaPak (ribavirin, USP) tablets that reduce pill burden and deliver treatment biologically equivalent to other ribavirin medications, and INFERGEN (interferon).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Kadmon company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Repertoire
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Repertoire
2.2 - Growth funds investing in similar companies to Repertoire
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Repertoire
4.2 - Public trading comparable groups for Repertoire
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →